EBR Systems Secures Final CMS Approval for TPT Reimbursement of WiSE CRT System.

EBR Systems, Inc. (ASX: EBR), a Silicon Valley-based company developing the world’s only wireless endocardial cardiac pacing device, has received final approval from the U.S. Centers for Medicare & Medicaid Services (CMS) for Transitional Pass-Through (TPT) reimbursement of its WiSE CRT System. The approval, effective from 1 October 2025 for a three-year period, will provide U.S. hospitals with incremental Medicare reimbursement when treating eligible outpatients with the WiSE System. This follows the previously approved New Technology Add-On Payment (NTAP) for inpatient use, also beginning on the same date, giving hospitals comprehensive reimbursement coverage.

The TPT program supports the adoption of breakthrough medical technologies that offer substantial clinical improvements but are not yet fully covered under standard Medicare rates. This milestone strengthens EBR’s commercial strategy, improves hospital adoption pathways, and significantly broadens patient access to its wireless pacing therapy. It marks a major step forward in advancing treatment options for heart failure patients across the U.S.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com